Journal article

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Sven O Friedrich, Andrea Rachow, Elmar Saathoff, Kasha Singh, Chacha D Mangu, Rodney Dawson, Patrick Pj Phillips, Amour Venter, Anna Bateson, Catharina C Boehme, Norbert Heinrich, Robert D Hunt, Martin J Boeree, Alimuddin Zumla, Timothy D McHugh, Stephen H Gillespie, Andreas H Diacon, Michael Hoelscher, undefined Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA)

Lancet Respir Med | Published : 2013

Abstract

BACKGROUND: An accurate biomarker is urgently needed to monitor the response to treatment in patients with pulmonary tuberculosis. The Xpert MTB/RIF assay is a commercially available real-time PCR that can be used to detect Mycobacterium-tuberculosis-specific DNA sequences in sputum samples. We therefore evaluated this assay with serial sputum samples obtained over 26 weeks from patients undergoing treatment for tuberculosis. METHODS: We analysed sputum samples from 221 patients with smear-positive tuberculosis enrolled at two sites (Cape Town, South Africa, and Mbeya, Tanzania) of a multicentre randomised clinical trial REMoxTB of antituberculosis treatment on a weekly basis (weeks 0 to 8),..

View full abstract

University of Melbourne Researchers